Abstract
Background: To optimize therapy for patients with human immunodeficiency virus-tuberculosis (HIV-TB) coinfection, we developed an ultra-high-performance liquid chromatography/- tandem mass spectrometry (UHPLC-MS) method to monitor seven second-line anti-tuberculosis drugs.
Methods: Blood samples (n = 70) were collected from 35 patients with HIV-TB coinfection; the plasma sample was protein-precipitated and diluted with a solution containing heptafluorobutyric acid. The plasma concentrations of rifabutin (RBT), clofazimine (CLO), moxifloxacin (MFX), prothionamide (PTH), levofloxacin (LFX), amikacin (AMK), and para-aminosalicylic acid (PAS) were detected by UHPLC-MS/MS method.
Results: In these 70 samples, the mean concentrations of RBT, CLO, MFX, PTH, LFX, and AMK were 173.8 (10.0–550.0), 61.1 (54.4–67.7), 646.6 (25.0–2480.0), 120.5 (50.0–597.0), 1565.9 (100.0–3480.0), and 10753.0 (400.0–76 700.0) μg/L, respectively. Only one sample was detected to have PAS with a concentration less than the lower limit of quantification. Most of the drug concentrations detected in these patients were lower than the targeted concentrations in TB patients.
Conclusion: We created a simple UHPLC-MS method for simultaneously quantifying anti-TB drugs. The plasma concentrations in HIV-TB co-infected patients were lower than the targeted concentrations. It is important to monitor anti-TB drugs in the future. This method will facilitate the monitoring of anti-TB drugs in the future.
Keywords: UHPLC-MS/MS, second-line anti-TB drugs, HIV-TB coinfection, drug-resistant tuberculosis, therapeutic drug monitoring, plasma.
Graphical Abstract
[http://dx.doi.org/10.1097/COH.0000000000000495] [PMID: 30080683]
[http://dx.doi.org/10.1371/journal.pone.0086614] [PMID: 24498278]
[http://dx.doi.org/10.1517/17425255.2014.895813] [PMID: 24597717]
[http://dx.doi.org/10.1016/S2352-3018(17)30109-1] [PMID: 28784426]
[http://dx.doi.org/10.1186/s13063-020-4132-7] [PMID: 32054536]
[http://dx.doi.org/10.1592/phco.27.6.793] [PMID: 17542762]
[http://dx.doi.org/10.1093/cid/ciu868] [PMID: 25362206]
[http://dx.doi.org/10.1586/ers.09.6] [PMID: 20477307]
[http://dx.doi.org/10.1016/S0140-6736(10)60410-2] [PMID: 20488523]
[http://dx.doi.org/10.1056/NEJMoa1901814] [PMID: 32130813]
[http://dx.doi.org/10.1007/s12098-020-03230-1] [PMID: 32103425]
[http://dx.doi.org/10.1007/s00228-016-2083-4] [PMID: 27305904]
[http://dx.doi.org/10.1136/bmjopen-2018-023899] [PMID: 30287613]
[http://dx.doi.org/10.1128/AAC.02410-17] [PMID: 29463539]
[http://dx.doi.org/10.1023/A:1012299115260] [PMID: 11768292]
[http://dx.doi.org/10.1007/s40265-014-0222-8] [PMID: 24846578]
[http://dx.doi.org/10.1097/FTD.0000000000000735] [PMID: 32004247]
[http://dx.doi.org/10.1080/17512433.2016.1235972] [PMID: 27626677]
[http://dx.doi.org/10.1093/jac/dky268] [PMID: 30124844]
[http://dx.doi.org/10.1093/jac/dkt154] [PMID: 23657802]
[http://dx.doi.org/10.2174/157488410791110797] [PMID: 20156156]
[http://dx.doi.org/10.4046/trd.2015.78.2.78] [PMID: 25861340]
[http://dx.doi.org/10.3343/alm.2016.36.5.489] [PMID: 27374716]
[http://dx.doi.org/10.3349/ymj.2015.56.4.961] [PMID: 26069117]
[http://dx.doi.org/10.2165/00003495-200262150-00001] [PMID: 12381217]
[http://dx.doi.org/10.1111/fcp.12374] [PMID: 29660162]
[http://dx.doi.org/10.1007/s40262-018-0716-8] [PMID: 30406475]
[http://dx.doi.org/10.1128/AAC.48.11.4473-4475.2004] [PMID: 15504887]
[http://dx.doi.org/10.1097/INF.0000000000001069] [PMID: 26825153]
[PMID: 15581206]
[http://dx.doi.org/10.1097/INF.0000000000001687] [PMID: 28719501]
[http://dx.doi.org/10.1093/jac/dkaa328] [PMID: 32785712]